地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18995651644
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理Independent Forensics品牌全系列产品
Independent Forensics 是一家法医 DNA 实验室,提供 DNA 测试,致力于为犯罪实验室、医学遗传学和人类个体识别领域开发新颖、创新且可靠的产品和服务。IFI的研究与开发涵盖面向执法机构的新产品、用于高灵敏度遗传识别的先进技术,以及面向健康专业人士和公众的新型基因检测方法。

▍Independent Forensics产品线
● AMPLICON RX™ KITS:DNA-STR多重检测扩增后回收技术;
● 显微镜套装:专为手动或自动化精子搜寻与细胞分离定制的蔡司显微镜及成像系统,并包含SPERM HY-LITER™ 精细胞检测试剂盒。
● iPLEX STR 检测试剂盒:用于18个STR基因座及Amelogenin基因检测的多重STR试剂盒。
● ONE TOUCH™ 试剂盒:适用于:接触DNA、指纹、粘性介质及激光捕获显微切割样本。
● 快速斑迹识别试剂盒:RSID™系列专为快速、简便、可靠地检测法医实验室遇到的各种样本中的特定人体体液而设计。
● SPERM HY-LITER™ 精细胞检测试剂盒:专为性侵证据设计的完整荧光染色试剂盒。特异性强。灵敏度高。操作灵活。支持自动化。
▍Independent Forensics部分产品列表
| 分类 | 货号 | 产品描述 |
| AMPLICON™ Rx 试剂盒 | 5999 | Amplicon Rx™ 10 检测/试剂盒 - 1/2 尺寸试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6000 | Amplicon Rx™ 20 检测试剂盒/试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6001 | Amplicon Rx™ 40 检测试剂盒/试剂盒 - 大试剂盒 |
| iPlex STR™ | 6600 | 96 次反应 |
| iPlex STR™ | 6500 | 48 次反应 |
| iPlex STR™ | 6400 | 24 次反应 |
| iPlex STR™ | 6600-310 | 310 基质标准品 |
| iPlex STR™ | 6600-3100 | 其他尺寸标准 |
| iPlex STR™ | 6600-3130 | 其他尺寸标准 |
| iPlex STR™ | 6600-3500 | 其他尺寸标准 |
| iPlex STR™ | 6600-S400 | 其他尺寸标准 |
| iPlex STR™ | 6700-M1 | iPLEX-STR™ 迷你 1 |
| iPlex STR™ | 6700-M2 | iPLEX-STR™ 迷你 2 |
| iPlex STR™ | 6800-Y | iPLEX-STR™ Y |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-LIFT | 一键式 DNA 免费提升卡 - 15 个/包 |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-CK | 一键式采集现场试剂盒 - 20 个无 DNA 拭子 + NDLB 采集缓冲液 |
| RSID™ Saliva Lab Kits | 0130 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Saliva Lab Kits | 0130-LARGE | RSID SALIVA UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Saliva Lab Kits | 0100 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Semen Field Kits | 2000-SMALL | 5 份检测试剂盒/试剂盒(小号 - 不包括剪刀和证据信封) |
| RSID™ Semen Field Kits | 2000 | 5 包/套件(用于现场的完整套件) |
| RSID™ Semen Field Kits | Oct-00 | 10 个测试/套件(小版 - 不包括剪刀和证据信封) |
| RSID™ Semen Lab Kits | 0230 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Semen Lab Kits | 0230-LARGE | RSID SEMEN UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Semen Lab Kits | 0200 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Urine Lab Kits | 0400-05 | 5 次检测/试剂盒,含缓冲液 |
| RSID™ Urine Lab Kits | 0400-10 | 10 次检测/试剂盒,含缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8000 | SPERM HY-LITER™ 疏水笔,用于勾勒涂片载玻片的轮廓 |
| Sperm Hyliter™ Replacement & Accessories | 8005 | 用于医院涂片载玻片的垫圈,矩形载玻片架,12 个/包 |
| Sperm Hyliter™ Replacement & Accessories | 8010 | 精子 HY-L™ 染色阳性对照玻片(指定 HY-LITER、EXPRESS 或 PI 染色) |
| Sperm Hyliter™ Replacement & Accessories | 8020 | SPERM HY-LITER™ 洗涤缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8030 | SPERM HY-LITER™ 封片剂 |
| Sperm Hyliter™ Replacement & Accessories | 8040 | SPERM HY-LITER™ 固定剂 |
| Sperm Hyliter™ Replacement & Accessories | 8050 | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT |
| Sperm Hyliter™ Replacement & Accessories | 8050-INT | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT - 国际运输 |
| Sperm Hyliter™ Express | 7301-MINI | Mini SPERM HY-LITER™ 试剂,用于染色 13、11 mm 孔或 26、8 mm 孔 |
| Sperm Hyliter™ Express | 7301 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ Express | 7302 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ Express | 7303 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ Express | 7302-SOS | SPERM HY-LITER™ SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ Express | 7303P | SPERM HY-LITER™ EXPRESS 大号套件,带 DTT,可选择载玻片和储物盒 |
| Sperm Hyliter™ Microscopes | 10078 | SPERMCAM - 2/3“ CCD 彩色相机,带 SpermCapture 软件,需要支持 C 接口的显微镜 |
| Sperm Hyliter™ Microscopes | 27777 | SPERM HY-LITER™ aureka 细胞分离系统,带染色试剂盒包和现场培训 |
| Sperm Hyliter™ Microscopes | 37777 | SPERM HY-LITER™ LCM 精子搜索、解剖系统与染色套件包和现场培训 |
| Sperm Hyliter™ Microscopes | custom | 提供替换显微镜部件和附件 - 物镜、灯泡、电线、橡胶目镜杯、防尘罩等。 |
| Sperm Hyliter™ Microscope Slides | 9108-25 | 精子 HY-L™ 1 x 8 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9108-26 | SPERM HY-LITER™ 1 x 8 mm, 25 张载玻片/包 & 存储盒 |
| Sperm Hyliter™ Microscope Slides | 9111-25 | 精子 HY-LITER™ 1 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9111-26 | SPERM HY-LITER™ 1 x 11毫米,25张幻灯片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9211-25 | 精子 HY-LITER™ 2 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9211-26 | SPERM HY-LITER™ 2 x 11 mm, 25张载玻片/包&存储盒 |
| Sperm Hyliter™ Microscope Slides | 9408-25 | 精子 HY-L™ 4 x 8 毫米,25 张玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9408-26 | SPERM HY-LITER™ 4 x 8 mm,25 张载玻片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9000-25 | 精子 HY-LITER™ 24 x 60 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9000-26 | SPERM HY-LITER™ 24 x 60 mm, 25张载玻片/包&储存盒 |
| Sperm Hyliter™ Microscope Slides | 9999-00 | SPERM HY-LITER™ 定制设计的显微镜载玻片 |
| Sperm Hyliter™ PI | 7401 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ PI 试剂 |
| Sperm Hyliter™ PI | 7402 | 中等精子 HY-LITER™ PI 试剂,用于染色 50、11 mm 孔或 100、8 mm 孔 |
| Sperm Hyliter™ PI | 7403 | 大精子 HY-LITER™ PI 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ PI | 7402-SOS | SPERM HY-LITER™ PI SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ PI | 7403-SOS | SPERM HY-LITER™ SOS - 新型溶液染色试剂盒,带国际 DTT,染色 150 个样品 |
| Sperm Hyliter™ | 7126 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ | 7150 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ | 7250 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ | 7250P | SPERM HY-LITER™ 大号套件,带 DTT,150 个 1x11 mm 孔载玻片和储存盒 |
| RSID™ Urine Field Kits | 4000 | 尿液 5 次检测/试剂盒,含预装尿液缓冲液、拭子、水和移液管 |
| RSID™ Urine Field Kits | 4000-10 | 尿液 10 次检测/试剂盒(同上 - 不包括剪刀或证据信封) |

艾美捷科技代理Magtivio品牌磁珠产品
荷兰Magtivio BV是一家磁性微/纳米颗粒生产商,为生命科学和生物分析领域提供磁珠及完整试剂盒产品。Magtivio BV设计开发了两种类型的二氧化硅包覆氧化铁磁珠,其中包括:超顺磁
性磁珠,它们采用复合多孔结构设计,易于再悬浮,并表现出较低的沉降率;以及铁磁性磁珠,这些磁珠粒型由相对致密的核壳结构制成,具有强磁性,更适合大体积和粘性样品。末端官能
化的基团可以连接到两种磁珠类型的二氧化硅涂层。Magtivio BV的产品包括:
(1)核酸纯化:MagSi-(D)NA试剂盒和磁珠作为固体支持相,从病原体、植物和动物组织、体液和细胞中分离核酸。
(2)DNA纯化:MagSi试剂盒,用于测序应用中的PCR 纯化、DNA大小选择。
(3)免疫测定:MagSi链霉亲和素珠用作固相,易于结合生物素化的生物分子。
(4)蛋白质分析:具有改性表面的MagSi微珠,用于蛋白质的纯化和分离,用于质谱、蛋白质组学分析和生物标志物研究。
(5)研究工具:表面活化的MagSi微珠,用于固定蛋白质、肽、核酸或其他感兴趣的分子;MagSi 平台具有广泛的功能化可能性。
(6)LCMS样品制备:在LC-MS/MS分析之前,基于MagSiMUS磁珠的生物样品制备,用于蛋白质耗竭和从生物样品中去除其他干扰化合物。
(7)SafeQ:用于样本采集、储存和释放的解决方案,例如唾液采集试剂盒
(8)磁选机:用于从液体样品中磁分离MagSi和MagSiMUS磁珠。
(9)rQ " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Magtivio品牌磁珠产品">
艾美捷科技代理Magtivio品牌磁珠产品
<艾美捷科技代理GenTegra品牌全系列产品
GenTegra 凭借专业的研发团队和深厚的技术积累,GenTegra 在生物样本保护领域处于领先地位,其产品广泛应用于科研、医疗、法医等多个领域。GenTegra 开发的产品包括适用于多种应用场景的样本采集装置,例如:用于基因组学和转录组学分析的 RNASeq 样本采集;对犯罪现场法医样本进行 DNA 分析的样本采集;来自患者自采样设备的全血样本采集。GenTegra公司的产品包括GenTegra RNA、GenTegra DNA。

▍GenTegra公司的产品
● GenTegra RNA 相关产品
①GenTegra RNA Advantage:使用 RIN 值作为 RNA 质量的衡量标准,能为组织中的 RNA 提供更好保护。相比 RNAlater 等产品,它始终产生 RIN 分数更好(≥1)的 RNA,且使用时 RIN 值等于或高于所需的 RIN 值≥7,确保出色的 RNAseq 结果,可替代 RNAlater 而无需更改当前方案。
②GenTegra RNA:是在实验室工作或运输 RNA 时为 RNA 提供的最佳保护产品。作为水溶性活性化学保护剂,添加到 RNA 中会形成保护基质,在干燥状态和液态下都能保存和保护 RNA。在 -80°C 至 +72°C 的极端温度下保护近乎完美,是唯一一种在干燥前立即提供 RNase 活性保护的干式储存产品,允许使用所有标准缓冲系统。在室温下储存保质期超过 3 年,有多种包装形式,如 100/0.5ml 螺旋盖管、96 孔微孔板或 96 管架格式、足够数量的散装基质,还提供三管评估套件。
③GenTegra RNAssure™:为 RNA 纯化和 RNAseq 的人员提供新水平的保护。其专有的活性化学保护™ ACP 配方可在洗脱纯化柱时立即保护 RNA,提供更彻底的保护,能保护样品完整性,可无缝融入每个标准 RNA 纯化试剂盒中,在室温(RT)下保护 RNA 至少 3 天,在 4°C 下保护 RNA 2 周,还可以保护 RNA 在 37°C 的较高温度下进行 DNase 处理期间免受损伤,能灭活纯化过程或环境污染遗留的所有残留 RNase 活性,保护 DNase 免受氧化损伤等。
● GenTegra - DNA 相关产品
①GenTegra - DNA:在运输和储存过程中的极端温度(-80°C 至 +72°C)下都能对 DNA 进行保护,基于加速研究在环境温度下保护 DNA 超过 20 年,无需特殊环境控制即可保护 DNA,经过多次干燥和补水循环。
②GenTegraDNA dry BULK:是法医实验室的首选产品,干散货是自动化系统的理想选择,支持直接用于 STR、qPCR 等,在需要时支持 DNA 样品浓缩,干燥的 DNA 样品可以在环境温度下安全运输,在室温下储存的保质期超过 3 年,提供三管评估套件。
● GenSolve DNA 提取和纯化试剂盒
①GenSolve Complete提取和纯化试剂盒:经过优化的提取和纯化方法,可提供最高质量的干血斑结果,能从任何可用的DNA采集卡中提取和纯化DNA,基于柱的纯化过程可有效将DNA与细胞碎片和外来化学成分分离。
②GenSolve DNA 提取试剂盒:可灵活地利用GenTegra 行业领先的DNA 提取技术来检测干血斑,并提供任何可用的DNA纯化试剂盒。来自任何采集卡的干血斑的 DNA 数量无与伦比,与GenTegra GenSaver卡或GenPlates结合使用时,产量为 95%,可与所需的任何DNA纯化方法配对。
▍GenTegra产品列表
| 产品名称 | 产品描述 |
| GenTegra RNAdvantage™ | 为新鲜组织样本中的 RNA 提供更优保护。 |
| GenTegra RNAssure™ | 对直接来源于 RNA 纯化试剂盒的 RNA 提供即时且完全的保护。 |
| GentegraRNA | 为运输用于 RNA 测序 (RNAseq) 的 RNA 提供即时且完全的保护。 |
| GenTegraDNA | 为生命科学和法医实验室应用提供卓越的 DNA 保护 |
| GenSolve COMPLETE 提取与纯化试剂盒 | 能够从干血斑中提取出最高质量、长度 >35 kb且高产量的 DNA。 |
| GenSolve 经典提取试剂盒 | 干血斑(DBS)DNA 提取技术可与任何 DNA 纯化试剂盒结合使用。 |
| GenTegra 快速干燥仪 | 可用于将生物样品施加到 GenTegra-RNA、GenTegra-DNA 或 GenPlate 之后进行干燥处理。 |
| enSaver DNA 卡 | 有 1 点、2 点和 4 点格式可供选择。变色格式适用于收集唾液等透明样本。 |
| GenSaver 2.0 法医 DNA 卡 | 该卡有 1 点、2 点和 4 点格式可供选择,其中变色格式适用于收集唾液等透明样本。 |

艾美捷科技代理Phenomenex品牌。
Phenomenex致力于开发新型分析化学解决方案,以解决工业、临床研究、政府和学术实验室中研究人员的分离和纯化挑战。
一些特色产品包括:
(1)稳健的生物制剂分析:采用新型钛 BioTi™ 生物相容性硬件,可最大限度地减少引发,四个颗粒平台可实现最佳多功能性,九个颗粒化学成分可最大限度地提高选择性和灵敏度。
(2)低流失气相色谱分离:Phenomenex Zebron 气相色谱柱产品组合涵盖广泛的应用。从最简单到最具挑战性的方法,Phenomenex的气相色谱柱技术使Phenomenex能够提供高性能和更快的分析,并实现最复杂基质的最佳分离度和分离。
(3)将样品净化时间缩短 40%:Strata-X PRO 是一种新型创新的固相萃取 (SPE) 吸附剂,可提供更快、更清洁的样品萃取方法,彻底改变传统的 SPE 方法。Strata-X PRO 提供改进且耐用的聚合物吸附剂性能,并结合基质去除技术,提供革命性的解决方案。使用更快的 SPE 方法,可将 SPE 方案的时间至少缩短 40%。无需活化或平衡的更少步骤可创建快速的 SPE 方法,而不会失去 SPE 净化样品的重要性。
(4)在任何系统上均具有超高性能:与传统的全多孔介质相比,Kinetex Core-Shell 技术在效率上有了显着的提高,可用于提高分辨率、显著提高生产率、减少溶剂消耗并降低成本。无论运行的是高效液相色谱 (HPLC) 还是超高效液相色谱 (UHPLC) 方法,Kinetex 核壳系列都能提供出色的性能。Phenomenex设计、制造和销售自己的二氧化硅和有机二氧化硅核壳颗粒。
< " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Phenomenex品牌"> 艾美捷科技代理Phenomenex品牌
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司,致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员,Helvetica Health Care通过了ISO 13485认证,在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板,适用于不同的分子测试平台和检测。这些产品有多种规格,可用于单一或多种分析物的检测,帮助实验室监控测试性能,确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制,满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖:抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。

▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
<艾美捷科技代理Essange Reagents品牌全系列产品
Essange Reagents的核心使命是开发与分销精密工程化试剂,专注于血型鉴定试剂及特定血浆蛋白产品的研发生产。这些试剂严格遵循ISO13485标准精心制备,适用于体外诊断(IVD)和科研专用(RUO),为研究人员与医疗从业者提供可靠、可重复的结果支撑,助力其精准达成科研目标。Essange Reagents的IgG亚类试剂及多数CD单克隆抗体(专用于诊断领域)均经过全面技术文献验证。
▎Essange Reagents产品线
● 血型血清学:Cellbind微柱凝集卡、抗血清、试剂红细胞、Cellbind卡专用Magister C24全自动系统;
● 免疫试剂:IgG亚类试剂、单核细胞活化检测试剂、ELISA产品以及其他生物制品。

▎Essange Reagents产品列表
| 品名 | 货号 | Product group | 规格 | Techique |
| PeliCluster Anti-Lactoferrin | M9160BBC | Cytokines Immune reagents | 5 mg | Flowcytometry |
| PeliCluster Anti-CD62P | M9048BBC | Cytokines Immune reagents | 5 mg | Flowcytometry |
| PeliCluster Anti-Granzyme B with azide | M9174ABD | Immune reagents | 10 mg | Flowcytometry |
| PeliCluster Anti-Granzyme B | M9174 | Immune reagents | 5 mg | Flowcytometry |
| Anti-Vedolizumab antibody | M9265 | Biologics | - | ELISA |
| Anti-Tocilizumab antibody | M9264 | Biologics | - | ELISA |
| Anti-Dupilumab antibody | M9263 | Biologics | - | ELISA |
| Anti-Guselkumab antibody | M9262 | Biologics | - | ELISA |
| Anti-Daratumumab antibody | M9261 | Biologics | - | ELISA |
| PeliKine Human IL-6 ELISA Rapid Set A | M2018 | MAT | - | - |
| PeliKine Human IL-6 ELISA Rapid Set B | M2019 | MAT | - | - |
| Cellbind P3-P | K7211 | Blood grouping reagents Column | 3x10 mL | Cellbind |
| PEG 4000 20% | K1159 | Blood grouping reagents Potentiator | 20 mL | PEG-IAT: spin tube |
| PeliLISS | K1110 | Blood grouping reagents Potentiator | 10 mL | LISS-IAT: spin tube |
| BSA 22% (bovine serum albumin) | K1106 | Blood grouping reagents Potentiator | 10 mL | BSA-IAT: spin tube |
| PeliClass human IgG subclass Plus control 2 | M1898 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus control 1 | M1897 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus calibrator set | M1896 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG4 Plus | M1894 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG3 Plus | M1893 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG2 Plus | M1892 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG1 Plus | M1891 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus kit | M1895 | IgG subclasses IMMAGE | - | Nephelometry/turbidimetry |
| Magister Control Software | K7320S2 | Blood grouping reagents Instruments Software | 1 piece | Cellbind |
| Magister Analysis Software | K7320S1 | Blood grouping reagents Instruments Software | 1 piece | Cellbind |
| Magister C24 | K7320 | Blood grouping reagents Instruments | 1 piece | Cellbind |
| HPE buffer | M1940 | Immune reagents | 55 mL | - |
| human IL-6 antibodies for ELISA | M9316 | Cytokines Immune reagents | - | - |
| Streptavidin poly-HRP | M2032 | Immune reagents | 1 mL | - |
| Cellbind Incubator | K7314 | Blood grouping reagents Instruments | - | - |
| Cellbind Centrifuge (12 cards) | K7312 | Blood grouping reagents Instruments | - | - |
| Cellbind Dispenser | K7300 | Blood grouping reagents Instruments | - | - |
| Streptavidin poly-HRP | M2051 | Immune reagents | 0,1 mL | - |
| Erytrocytenserologie | K3010 | Blood grouping reagents Educational services | - | - |
| Immunohaematology | K3010EN | Blood grouping reagents Educational services | - | - |
| PeliControl | K1379 | Blood grouping reagents Control | 2x8 ml | - |
| Cellbind DILUENT | K7180 | Blood grouping reagents Column | 100 mL | Cellbind |
| Cellbind LISS | K7130 | Blood grouping reagents Column | 3x25 mL | Cellbind |
| MASPAT Indicator Red Cells | K1139 | Blood grouping reagents Platelet crossmatch | 10 mL | - |
| Cellbind LISS | K7110 | Blood grouping reagents Column | 100 mL | Cellbind |
| MASPAT kit | K1360 | Blood grouping reagents Platelet crossmatch | 96 tests | - |
| MAT Cell Set HS | M2017 | MAT | - | - |
| PeliStrip elution kit | K1398 | Blood grouping reagents Elution | 15 tests | PEG DAT/IAT; spin tube |
| MAT Cell Set | M2016 | MAT | - | - |
| Makropanel 16 | K1385 | Blood grouping reagents Cells | 16x3 mL | IAT: spin tube |
| Screening panel 123 | K1148 | Blood grouping reagents Cells | 3x10 mL | IAT: spin tube |
| Cellbind ID16 | K7230 | Blood grouping reagents Column | 16x3 mL | Cellbind |
| Cellbind P3 | K7210 | Blood grouping reagents Column | 3x10 mL | Cellbind |
| Cellbind P2 | K7200 | Blood grouping reagents Column | 2x10 mL | Cellbind |
| Cellbind B reagent red cells | K7242 | Blood grouping reagents Column | 10 mL | Cellbind |
| Pelikloon polyspecific anti-human serum | K1193 | Blood grouping reagents Coombs sera | 10 mL | (LISS or albumin)-IAT/DAT; spin tube |
| MabTrack ADA infliximab | M2960 | Biologics | - | ELISA |
| Pelikloon anti-C3d monoclonal | K1377 | Blood grouping reagents Coombs sera | 10 mL | DAT; spin tube |
| MabTrack ADA adalimumab | M2950 | Biologics | - | ELISA |
| Pelikloon enhanced control | K1152 | Blood grouping reagents Control | 10 mL | - |
| MabTrack level infliximab | M2920 | Biologics | - | ELISA |
| MabTrack level adalimumab | M2910 | Biologics | - | ELISA |
| Monospecific anti-human IgG (goat) | K1131 | Blood grouping reagents Coombs sera | 10 mL | (LISS or PEG)-IAT/DAT; spin tube |
| anti-H (lectin) saline method | K1327 | ABO Blood grouping reagents | 3 mL | Saline: spin tube |
| Cellbind A1 reagent red cells | K7240 | Blood grouping reagents Column | 10 mL | Cellbind |
| anti-A1 (lectin) saline method | K1328 | ABO Blood grouping reagents | 5 mL | Saline: spin tube, MTP |
| Pelikloon anti-D mix (IgG/IgM) monoclonal | K1157 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, IAT, MTP, Cellbind |
| Pelikloon control monoclonal | K1156 | Blood grouping reagents Control | 10 mL | - |
| anti-Wra AGT method | K1344 | Blood grouping reagents Rare | 3 mL | IAT: spin tube |
| anti-s AGT method | K1343 | Blood grouping reagents Rare | 3 mL | IAT, spin tube |
| anti-Fyb AGT method | K1337 | Blood grouping reagents Rare | 3 mL | IAT, spin tube |
| Pelikloon anti-k (IgM) monoclonal | K1310 | 2 mL | Saline, spin tube | |
| Anti-Fya (IgG) monoclonal AGT method | K1236 | Blood grouping reagents Rare | 3 mL | IAT, spin tube, Cellbind |
| Pelikloon anti-Leb (IgA) monoclonal | K1317 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-K (IgM) monoclonal | K1199 | Blood grouping reagents Rare | 5 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-Lea (IgM) monoclonal | K1306 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-P1 (IgM) monoclonal | K1305 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-D enhanced (IgM) monoclonal | K1151 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-D (IgM) monoclonal | K1255 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-S (IgM) monoclonal | K1304 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-N (IgG) monoclonal | K1313 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-M (IgG) monoclonal | K1302 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Cellbind Direct Type | K7012 | ABO Column | 48 | Cellbind |
| Pelikloon anti-Jkb (IgM) monoclonal | K1301 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-Jka (IgM) monoclonal | K1300 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-Cw (IgM) monoclonal | K1201 | Blood grouping reagents Rhesus | 2 mL | Saline, spin tube |
| Cellbind Screen | K7000 | Blood grouping reagents Column | 48 cards | Cellbind |
| Pelikloon anti-e (IgM) monoclonal | K1205 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-E (IgM) monoclonal | K1204 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-c (IgM) monoclonal | K1203 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-C (IgM) monoclonal | K1202 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-e (IgM) monoclonal | K1197 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-c (IgM) monoclonal | K1196 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-C (IgM) monoclonal | K1195 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-E (IgM) monoclonal | K1191 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-A,B (IgM) monoclonal | K1190 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-B (IgM) monoclonal | K1189 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-A (IgM) monoclonal | K1188 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |
<艾美捷科技代理Clearsynth品牌全系列产品
Clearsynth研发中心位于海得拉巴,以“创新与精准之心”为核心理念,打造了一个精心设计的空间,旨在激发突破性的发现并提升可能性的界限。专注于创新有机化学和独特复杂分子的合成,涵盖稳定同位素标记化合物、代谢物、杂质、葡萄糖醛酸、手性化合物、共轭物杂质和放射性标记化合物等。承接复杂分子或“难以合成”的合成化合物/中间体的定制合成服务。提供超过3,59,000个高纯度参考标准品,Clearsynth公司的产品线包括稳定同位素、原料药、杂质、亚硝胺、二级标准、散装化合物等。

▍Clearsynth服务领域
● 小分子:合成各种精细化学品和化合物,用于从毫克到数公斤规模的小分子药物发现。
● 工艺开发:开发新的合成路线,也可以修改和优化客户提供的工艺。
● 合同研发综合:专注于从临床前阶段到III期以及成功的技术转让。
● 生物核磁共振服务:位于海得拉巴的符合GLP标准的高场生物核磁共振/600MHz和300MHz设施,由敬业且经验丰富的核磁共振操作员提供支持。
● CDMO服务:致力于复杂、危险和可持续的产品和工艺。
● 分析服务:符合FDA、BIS、卫生部和其他标准机构制定的所有监管规范。
▍Clearsynth部分产品列表
| 品名 | 货号 | CAS号 |
| α-Keto Isovaleric Acid Sodium Salt 13C D6 | CS-R-00562 | 3715-29-5 (Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt 13C5 | CS-R-00482 | 1173018-24-0 |
| α-Keto Isovaleric Acid Sodium Salt D6 | CS-R-00485 | 3715-29-5(Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt Dimethyl-13C2 | CS-R-00488 | 634908-42-2 |
| α-KETOBUTYRIC ACID, SODIUM 13C, D4 | CS-R-00475 | 2013-26-5 (Unlabeled) |
| α-KETOBUTYRIC ACID, SODIUM SALT 13C4, D2 | CS-R-00477 | 360769-17-1 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C | CS-R-00478 | 634908-43-3 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C, D2 | CS-R-00479 | 1007476-77-8 |
| α-Ketobutyric Acid-d2 Sodium Salt | CS-T-30294 | 1007476-82-5 |
| α-Ketoglutaric acid 13C2, D2 | CS-CX-00331 | 123953-28-6 |
| α-KETOGLUTARIC ACID 13C5 | CS-R-00549 | 161096-83-9 |
| α-KETOGLUTARIC ACID, DISODIUM SALT 13C4 | CS-R-00480 | 1429051-79-5 |
| α-KETOISOCAPROIC ACID 13C | CS-R-00551 | 92751-19-4 |
| α-KETOISOCAPROIC ACID, SODIUM SALT 13C2 | CS-R-00552 | 4502-00-5(Unlabeled) |
| α-KETOISOCAPROIC ACID, SODIUM SALT ISOPROPYL-D7 | CS-R-00555 | 1795020-84-6 |
| α-Tocopherol-[13C3] | CS-I-00340 | 59-02-9 (Unlabeled) |
| β-ALANINE 13C | CS-R-00042 | 65138-34-3 |
| β-ALANINE 13C, 15N | CS-R-00449 | 1822942-84-6 |
| β-ALANINE 13C3 | CS-R-00040 | 107-95-9 (Unlabeled) |
| β-ALANINE 15N | CS-R-00041 | 204451-53-6 |
| β-CAROTENE 13C4 | CS-R-00567 | 7235-40-7(Unlabeled) |
| -β-Cyclocitral-d5 | CS-T-51410 | 78995-98-9 |
| β-Endosulfan D4 | CS-O-15034 | 203716-99-8 |
| β-Ionone-[13C3] | CS-I-00368 | 14901-07-6 (Unlabeled) |
| βmethasone 17-propionate-d3 | CS-O-10426 | 5534-13-4 (Unlabeled) |
| β-Tocopherol-[13C9] | CS-I-00341 | 59-02-9 (Unlabeled) |
| γ-HCH D6 | CS-EJ-0009 | 60556-82-3 |
| (-)-(2S,3S)-Viridifloric Acid Acetonide-d7 | CS-T-102816 | 95462-09-2(Unlabelled) |
| (-)-(2S,3S)-Viridifloric Acid Ethyl Ester-d7 | CS-T-102815 | 176712-53-1(Unlabelled) |
| (-)-(3S)-3-Hydroxy Quinine-vinyl-d3 | CS-T-101262 | 2734920-65-9 |
| (-)-(S)-Cibenzoline-D4 | CS-O-33254 | 103419-18-7 (Unlabeled) |
| (-)-2-Amino-6-propionamido-d3-tetrahydrobenzothiazole | CS-T-97805 | 1217644-20-6 |
| (-)-2-Methyl Isoborneol-d3 | CS-T-58298 | 135441-89-3 |
| (-)-alfa-Benidipine-d5 Hydrochloride | CS-P-07295 | 129262-07-3 (Unlabeled) |
| (-)-Cannabidiol-d9 | CS-TA-86322 | 1246819-21-5 |
| (-)-Citrinin-13C,d2 | CS-T-72877 | 1329611-85-9 |

艾美捷科技代理HMGBiotech品牌产品。
高迁移率族蛋白B1(HMGB1)是一种高度保守的核蛋白,广泛分布于哺乳动物细胞。随着其晚期促炎作用的发现,HMGB1成为近年来研究的热点之一。HMGBiotech是
一家专注于为HMGB领域的研究人员和公司提供试剂、服务的公司;值得注意的是,HMGBiotech公司,是目前位数不多的,生产HMGB1蛋白氧化还原变体的供应商。
HMGB1在基因组的组织和表达中具有多种功能:当细胞因损伤(病毒、机械或化学创伤、中毒)而死亡时,HMGB1 被释放并被附近细胞中的受体吸收。此外,处于严重
压力下的细胞甚至在死亡前会分泌HMGB1;存活的细胞会发出一系列反应 - 炎症 - 并试图替换死细胞并重建受损组织。HMGB1能够促进恢复和再生,;然而,过多的
HMGB1与脓毒症、关节炎、动脉粥样硬化和癌症转移有关。HMGBiotech主要产品包括:
(1)细胞
来自 Hmgb1 野生型和 Hmgb1 敲除细胞的对照细胞裂解物
Hmgb1敲除小鼠胚胎成纤维细胞
Hmgb2敲除小鼠胚胎成纤维细胞
(2)质粒
HMGB1 质粒
RAGE 质粒
(3)蛋白质试剂盒
HMGB1亚型试剂盒
(4)不含LPS的HMGB1重组蛋白
(5)稳定标记的蛋白质
HMGB1 15N 标记用于质谱和 NMR
用于核磁共振的 SDF-1 15N 和 13C
SDF-1 15N 用于质谱和 NMR
(6)抗体
ANTI HMGB1单克隆抗体
< " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理HMGBiotech品牌"> 艾美捷科技代理HMGBiotech品牌
<艾美捷科技代理CortecNet品牌全系列产品
CortecNet成立于1995年,是一家以稳定同位素为核心驱动的公司,致力于在 NMR、质谱(MS)、磁共振成像(MRI)和PET领域识别、开发和营销创新产品。这些技术在表征蛋白质、生物分子及材料的结构与动力学,以及在代谢成像应用中发挥着关键作用。CortecNet已与国际领先公司和机构建立了牢固的合作关系,开发了利用大肠杆菌、昆虫细胞、哺乳动物细胞和无细胞表达系统进行稳定同位素标记蛋白表达的创新策略。
▍CortecNet产品线
● NMR &Analytica:聚焦于核磁共振技术相关的应用场景,具体产品包括氚代溶剂、D2O回收等一系列与核磁共振分析相关产品和耗材等。
● Nuclear Medicine & lmaging:核医学和成像领域,具体产品有核医学相关业务、超极化MRI以及氚代谢成像等。
● Industry Applications:具体产品涵盖OLED相关,氚代药物、电子领域、体内研究以及能源领域等。
| 应用领域 | 目录 |
| NMR &Analytica | Deuterated Solvents;Cell Free Kits;Labeled Amino Acids;All Stable lsotopes;NMR Consumables &Accessories;DNP Radicals;EPR Consumables |
| Nuclear Medicine & lmaging | Nuclear Medicine;Hyperpolarized-MR;Deuterium Metabolic lmaging |
| Industry Applications | OLED;Deuterated Drugs;Electronic;In Vivo;Energy |

▍CortecNet部分产品列表
| 品名 | 货号 | 规格 | CAS号 |
| 1,2-Dichlorobenzene-d4 | S-2509X-V09B | 1 x 5 mL | 2199-69-1 |
| 1,4-Dichlorobenzene-d4 | S-3009X-M05B | 1 x 5 g | 3855-82-1 |
| Acetic acid-d4 | S-0108X-V04A;S-0108X-V11B;S-0105X-V04A | 2 x 0.75 mL;1 x 10 mL;2 x 0.75 mL | 1186-52-3 |
| Acetone-d6 | S-0206X-V06A;S-0206X-V12S;S-0206X-V14B | 10 x 0.75 mL;5 x 10 mL Septum Vial;1 x 25 mL | 666-52-4 |
| Acetone-d6 with TMS | S-0203B-V06A | 10 x 0.75 mL | 666-52-4 |
| Acetonitrile-d3 | S-0306X-V06A;S-0306X-V11S;S-0306X-V10B | 10 x 0.75 mL;1 x 10 mL Septum Vial;1 x 5 mL | 2206-26-0 |
| Acetonitrile-d3 with TMS | S-0303B-V04A | 2 x 0.75 mL | 2206-26-0 |
| Benzene-d6 | S-0408X-V06A;S-0408X-V12S;S-0408X-V14B | 10 x 0.75 mL;5 x 10 mL Septum Vial;1 x 25 mL | 1076-43-3 |
| Benzene-d6 with TMS | S-0408B-V10B | 1 x 5 mL | 1076-43-3 |
| Chloroform-d | S-0503X-V03A;S-0506X-V03A;S-0506X-V11B | 10 x 0.60 mL;10 x 0.6 mL;1 x 10 mL | 865-49-6 |
| Chloroform-d with TMS | S-0503B-V03A;S-0503B-V14B;S-0506B-V14B | 10 x 0.6 mL;1 x 25 mL;1 x 25 mL | 865-49-6 |
| Cyclohexane-d12 | S-0608X-V04A;S-0608X-V10B | 2 x 0.75 mL;1 x 5 mL | 1735-17-7 |
| Deuterium Oxide | W-0403E-V03A;W-0405E-V14B;W-0403E-V14B | 10 x 0.60 mL;1 x 25 mL;1 x 25 mL | 7789-20-0 |
| Dimethylformamide-d7 | S-0708X-V04A;S-0708X-V10B | 2 x 0.75 mL;1 x 5 mL | 4472-41-7 |
| Dimethylsulfoxide-d6 | S-0806X-V06A;S-0806X-V12S;S-0806X-V14B | 10 x 0.75 mL;5 x 10 mL Septum Vial;1 x 25 mL | 2206-27-1 |
| Dimethylsulfoxide-d6 with TMS | S-0806B-V14B;S-0806B-V12S;S-0803B-V06A | 1 x 25 mL;5 x 10 mL;10 x 0.75 mL | 2206-27-1 |
| Dioxane-d8 | S-0909X-V08A | 2 x 1 mL | 17647-74-4 |
| DSS | DSSPF | 1 g | 2039-96-5 |
| Ethanol-d6 | S-1009X-V08A;S-1009X-V10B | 2 x 1 mL;1 x 5 mL | 1516-08-1 |
| Hexafluoroisopropanol-d2 | S-1109X-V08A;S-1109X-V10B | 2 x 1 mL;1 x 5 mL | 38701-74-5 |
| Isopropanol-d8 | S-1209X-M06B | 1 x 10 g | 22739-76-0 |
| Methanol-d1 | S-2709X-V14B | 1 x 25 mL | 1455-13-6 |
| Methanol-d3 | S-2806X-V06A;S-2806X-V10B | 10 x 0.75 mL;1 x 5 mL | 1849-29-2 |
| Methanol-d4 | S-1306X-V06A;S-1306X-V12S;S-1306X-V14B | 10 x 0.75 mL;5 x 10 mL Septum Vial;1 x 25 mL | 811-98-3 |
| Methanol-d4 with TMS | S-1306B-V06B;S-1306B-V11B | 10 x 0.75 mL;1 x 10 mL | 811-98-3 |
| Methylene Chloride-d2 | S-1506X-V06A;S-1506X-V14B;S-1506X-V11B | 10 x 0.75 mL;1 x 25 mL;1 x 10 mL | 1665-00-5 |
| Pyridine-d5 | S-1608X-V06A;S-1608X-V14B;S-1608X-V11B | 10 x 0.75 mL;1 x 25 mL;1 x 10 mL | 7291-22-7 |
| Sodium Deuteroxide | S-1708X-M08B | 1 x 50 g | 14014-06-3 |
| Sulfuric Acid-d2 | S-2911X-M06B | 1 x 10 g | 7664-93-9 |
| Tetrachloroethane-d2 | S-1807X-V14B;S-1807X-V11B | 1 x 25 mL;1 x 10 mL | 33685-54-0 |
| Tetrahydrofuran-d8 | S-1908X-V04A;S-1908X-V08A;S-1908X-V11B | 2 x 0.75 mL;2 x 1 mL;1 x 10 mL | 7291-22-7 |
| TMSP-d4 | S-2410X-M02B | 1 g | 24493-21-8 |
| Toluol-d8 | S-2007X-V04A;S-2007X-V14B;S-2007X-V11B | 2 x 0.75 mL;1 x 25 mL;1 x 10 mL | 2037-26-5 |
| Trifluoroacetic Acid-d1 | S-2108X-V04A;S-2108X-V11B | 2 x 0.75 mL;1 x 10 mL | 599-00-8 |
| Trifluoroethanol-d2 | S-2210X-V04A | 2 x 0.75 mL | 77568-66-2 |
| Trifluoroethanol-d3 | S-2309X-V04A | 2 x 0.75 mL | 77253-67-9 |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18995651644
邮箱:sales@amyjet.com
0.2141